Ruth Em Ashton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruth Em Ashton has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Mark Anthony Faghy
School of Sport, Exercise and Health Sciences Loughborough University Loughborough UK
8 shared publications Tom Bewick
University Hospitals of Derby and Burton NHS Foundation Trust
5 shared publications- Callum Thomas
School of Health, Sport and Rehabilitation University of Derby Derby UK
4 shared publications - Rebecca Owen
Biomedical and Clinical Science Research Theme, School of Human Sciences, University of Derby, Derby, UK
4 shared publications Lindsay Skipper
Biomedical and Clinical Science Research Theme, School of Human Sciences, University of Derby, Derby, UK
3 shared publications- Amber Lord
Peninsula Clinical Trials Unit, University of Plymouth
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21  (10) , e0360525
Blood biomarkers of long COVID: A cross-sectional evaluation of key cytokines and the coordination of inflammation
Introduction: Long COVID is a complex pathophysiological condition linked to a heterogenous symptom profile. Dysregulation of 1) immunological and inflammatory responses, 2) endothelial/vascular function, and 3) metabolic and clotting processes have been identified; however, there remains a lack of clinically validated diagnostic biomarkers. The study aim was to investigate dysregulation of cytokines, chemokines and growth factors in confirmed Long COVID cases grouped by disease severity. Methods: One-hundred-and-twenty-seven participants provided venous blood samples for cytokine profiling utilising Luminex assays. Participants were grouped into those with no knowledge of SARS-CoV-2 infection (n = 21), acute infection within 3-months (n = 22), spontaneous resolvers (>3-months, n = 21) and those with confirmed Long COVID (n = 63). Long COVID severity was grouped according to the post-COVID-19 functional status (PCFS) and defined as those with negligible (4A; n = 9), mild (4B; n = 20), moderate (4C; n = 24), and severe limitations (4D; n = 10). Cytokines were assessed for normality using Shapiro-Wilk tests and differences measured between groups using Kruskal-Wallis tests. Pairwise correlation and principal component analysis were performed. Results: Interleukin-12 (p40/p70) was 22% greater in the Long COVID group (Median [IQR]: 58 [49] pg/mL, p = 0.046) and 30% greater in the acutely infected group (64 [36] pg/mL; p = 0.039) against non-infected controls (45 [25] pg/mL). Following PCFS classification, fibroblast growth factor-basic was 25% lower in Long COVID 4B versus spontaneous resolvers (24 [7] vs. 32 [24] pg/mL; p = 0.025). Pairwise correlation differences demonstrated that three Long COVID subgroups had strong, positive associations between cytokines when compared to non-infected controls; however, PCA was unable to determine any coordinated cytokine variation that was group specific. Discussion and conclusions: Elevated interleukin-12 (p40/p70) and reduced basic fibroblast growth factor suggest persistent immune activation and possible subgroup-specific Long COVID; however, these findings were marginally significant and exploratory. A coordinated but partial immunological/inflammatory profile may exist in some of those with Long COVID, suggesting a rationale for subgrouping upon a biological, rather than self-report basis but larger longitudinal studies are required to confirm this hypothesis.
- 21 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21  (10) , e0360525
Open AccessBlood biomarkers of long COVID: A cross-sectional evaluation of key cytokines and the coordination of inflammation
Introduction: Long COVID is a complex pathophysiological condition linked to a heterogenous symptom profile. Dysregulation of 1) immunological and inflammatory responses, 2) endothelial/vascular function, and 3) metabolic and clotting processes have been identified; however, there remains a lack of clinically validated diagnostic biomarkers. The study aim was to investigate dysregulation of cytokines, chemokines and growth factors in confirmed Long COVID cases grouped by disease severity. Methods: One-hundred-and-twenty-seven participants provided venous blood samples for cytokine profiling utilising Luminex assays. Participants were grouped into those with no knowledge of SARS-CoV-2 infection (n = 21), acute infection within 3-months (n = 22), spontaneous resolvers (>3-months, n = 21) and those with confirmed Long COVID (n = 63). Long COVID severity was grouped according to the post-COVID-19 functional status (PCFS) and defined as those with negligible (4A; n = 9), mild (4B; n = 20), moderate (4C; n = 24), and severe limitations (4D; n = 10). Cytokines were assessed for normality using Shapiro-Wilk tests and differences measured between groups using Kruskal-Wallis tests. Pairwise correlation and principal component analysis were performed. Results: Interleukin-12 (p40/p70) was 22% greater in the Long COVID group (Median [IQR]: 58 [49] pg/mL, p = 0.046) and 30% greater in the acutely infected group (64 [36] pg/mL; p = 0.039) against non-infected controls (45 [25] pg/mL). Following PCFS classification, fibroblast growth factor-basic was 25% lower in Long COVID 4B versus spontaneous resolvers (24 [7] vs. 32 [24] pg/mL; p = 0.025). Pairwise correlation differences demonstrated that three Long COVID subgroups had strong, positive associations between cytokines when compared to non-infected controls; however, PCA was unable to determine any coordinated cytokine variation that was group specific. Discussion and conclusions: Elevated interleukin-12 (p40/p70) and reduced basic fibroblast growth factor suggest persistent immune activation and possible subgroup-specific Long COVID; however, these findings were marginally significant and exploratory. A coordinated but partial immunological/inflammatory profile may exist in some of those with Long COVID, suggesting a rationale for subgrouping upon a biological, rather than self-report basis but larger longitudinal studies are required to confirm this hypothesis.
- Open Access
An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial
Objective: Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the feasibility of a five‑day IV remdesivir intervention for individuals with LC. Methods: Seventy-three participants aged ≥18 years with a confirmed LC diagnosis were recruited across two sites in the United Kingdom to receive a five‑day course of IV remdesivir. Primary feasibility outcomes included recruitment, treatment completion, acceptability, and safety. Exploratory patient-reported (e.g. Fatigue Assessment Scale [FAS]) and clinical outcomes (e.g. 6-minute walk test [6MWT]) were also collected. Results: Of 106 individuals screened, 73 were enrolled and 71 (97%) completed the 5-day IV remdesivir regimen. Follow-up assessments were completed by 70 participants (96%), with high completion rates observed across clinical assessments, patient-reported outcomes and symptom tracking. No severe adverse reactions were reported. Improvements were also observed in several exploratory patient-reported and clinical outcomes. Conclusion: We demonstrated the feasibility and acceptability of administering IV remdesivir in people with LC. Analysis of secondary outcomes suggests therapeutic promise, but rigorous evaluation in large-scale randomised controlled trials is essential to determine the true efficacy and clinical utility of intravenous remdesivir in this population.
Open AccessAn Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial
Objective: Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the feasibility of a five‑day IV remdesivir intervention for individuals with LC. Methods: Seventy-three participants aged ≥18 years with a confirmed LC diagnosis were recruited across two sites in the United Kingdom to receive a five‑day course of IV remdesivir. Primary feasibility outcomes included recruitment, treatment completion, acceptability, and safety. Exploratory patient-reported (e.g. Fatigue Assessment Scale [FAS]) and clinical outcomes (e.g. 6-minute walk test [6MWT]) were also collected. Results: Of 106 individuals screened, 73 were enrolled and 71 (97%) completed the 5-day IV remdesivir regimen. Follow-up assessments were completed by 70 participants (96%), with high completion rates observed across clinical assessments, patient-reported outcomes and symptom tracking. No severe adverse reactions were reported. Improvements were also observed in several exploratory patient-reported and clinical outcomes. Conclusion: We demonstrated the feasibility and acceptability of administering IV remdesivir in people with LC. Analysis of secondary outcomes suggests therapeutic promise, but rigorous evaluation in large-scale randomised controlled trials is essential to determine the true efficacy and clinical utility of intravenous remdesivir in this population.
- Open Access
- 4 March 2026
- Published by Springer Nature in Research Square
An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID
Background: Long COVID (LC) affects around two million people in the United Kingdom and over 65 million people globally. Antiviral medications have shown positive effects in reducing the risk of progression to severe disease in high-risk patients during an acute SARS-CoV-2 infection and improved outcomes in those living with LC. Research testing the feasibility and efficacy of anti-viral medications is ongoing, and clinical trials should determine the use of Remdesivir and its impact on LC symptoms, patient-reported outcomes, quality of life and functional status. Methods: Seventy-two patients ≥ 18 years of age who have a confirmed LC diagnosis will be recruited across two sites to trial Remdesivir TM treatment delivered via intravenous infusion over 5 days. This feasibility study will provide high-quality data to estimate screening rates, recruitment through different pathways, retention and treatment adherence. The study will also determine the definitive trial’s most clinically relevant primary outcome. After a detailed screening process, patient-reported and clinical outcome measures (including EQ-5D-5L, Symptom Burden Questionnaire™ for LC [SBQ™], cardio-pulmonary exercise tests (CPET), lung function, biomarkers and inflammatory profiles) will be collected to determine symptoms and impact of their condition, which will be repeated post-treatment. A subset of 20 participants will undergo parametric [ 18 ] Fluorodeoxyglucose (FDG) to measure multi-organ metabolic activity. Due to the established physical, cognitive and clinical impairment impacts of LC, patient involvement has been extensively embedded within the design and implementation of all study processes to increase patient safety and delivery. Discussion: This study will provide data on the feasibility of a trial of 5-day intravenous treatment with Remdesivir for patients with LC. The treatment is already effective in the treatment of patients with acute severe cases of SARS-CoV-2. Remdesivir has an established safety profile and carries no higher risk to patients than standard medical care. The findings will inform the design of a future definitive study. Registration details ISRCTN Number: 72940450 Date registered: 07/06/2024 URL: https://www.isrctn.com/ISRCTN72940450 ClinicalTrials.gov Number: NCT05911906
- 4 March 2026
- Published by Springer Nature in Research Square
Open AccessAn open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID
Background: Long COVID (LC) affects around two million people in the United Kingdom and over 65 million people globally. Antiviral medications have shown positive effects in reducing the risk of progression to severe disease in high-risk patients during an acute SARS-CoV-2 infection and improved outcomes in those living with LC. Research testing the feasibility and efficacy of anti-viral medications is ongoing, and clinical trials should determine the use of Remdesivir and its impact on LC symptoms, patient-reported outcomes, quality of life and functional status. Methods: Seventy-two patients ≥ 18 years of age who have a confirmed LC diagnosis will be recruited across two sites to trial Remdesivir TM treatment delivered via intravenous infusion over 5 days. This feasibility study will provide high-quality data to estimate screening rates, recruitment through different pathways, retention and treatment adherence. The study will also determine the definitive trial’s most clinically relevant primary outcome. After a detailed screening process, patient-reported and clinical outcome measures (including EQ-5D-5L, Symptom Burden Questionnaire™ for LC [SBQ™], cardio-pulmonary exercise tests (CPET), lung function, biomarkers and inflammatory profiles) will be collected to determine symptoms and impact of their condition, which will be repeated post-treatment. A subset of 20 participants will undergo parametric [ 18 ] Fluorodeoxyglucose (FDG) to measure multi-organ metabolic activity. Due to the established physical, cognitive and clinical impairment impacts of LC, patient involvement has been extensively embedded within the design and implementation of all study processes to increase patient safety and delivery. Discussion: This study will provide data on the feasibility of a trial of 5-day intravenous treatment with Remdesivir for patients with LC. The treatment is already effective in the treatment of patients with acute severe cases of SARS-CoV-2. Remdesivir has an established safety profile and carries no higher risk to patients than standard medical care. The findings will inform the design of a future definitive study. Registration details ISRCTN Number: 72940450 Date registered: 07/06/2024 URL: https://www.isrctn.com/ISRCTN72940450 ClinicalTrials.gov Number: NCT05911906
- Open Access
- 7 February 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04006
Profiling the persistent and episodic nature of long COVID symptoms and the impact on quality of life and functional status: a cohort observation study
Symptoms of acute viral infections that persist in the weeks, months, and years’ post-infection are collectively referred to as post-viral illnesses. The most devastating epidemic in recorded history was the 1918 Spanish Flu epidemic, with an estimated global mortality between 24–50 million people over three distinct waves of infection [1]. Of particular interest was the […]
- 7 February 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04006
Open AccessProfiling the persistent and episodic nature of long COVID symptoms and the impact on quality of life and functional status: a cohort observation study
Symptoms of acute viral infections that persist in the weeks, months, and years’ post-infection are collectively referred to as post-viral illnesses. The most devastating epidemic in recorded history was the 1918 Spanish Flu epidemic, with an estimated global mortality between 24–50 million people over three distinct waves of infection [1]. Of particular interest was the […]
- Open Access
- 9 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 62, 102145
Forming a consensus opinion to inform long COVID support mechanisms and interventions: a modified Delphi approach
- 9 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 62, 102145
Open AccessForming a consensus opinion to inform long COVID support mechanisms and interventions: a modified Delphi approach
- Top Cited PapersOpen Access
Lived experience of patients with Long COVID: a qualitative study in the UK
Background Long COVID is a rapidly evolving global health crisis requiring interdisciplinary support strategies that incorporate the lived experience of patients. Currently, there is a paucity of research documenting the day-to-day experiences of patients living with Long COVID. Objective To explore the lived experience of Long COVID patients. Study design Longitudinal, observation study. Setting An inductive, data-driven, qualitative approach was used to evaluate hand-written diaries obtained from individuals who had been referred to a Derbyshire Long COVID clinic. Participants 12 participants (11 females, age 49±10 years, 11 Caucasians) were recruited. Participants were included if they had a previous confirmed or suspected COVID-19 infection with ongoing recovery, >18 years old, understood the study requirements and provided informed consent. Method Participants were directed to complete self-report diaries over 16 weeks. Responses were transcribed verbatim and analysed using thematic analysis. Results Three key themes were highlighted: (1) understanding who helps patients manage symptoms, (2) daily activities and the impact on quality of life and health status and (3) the effect of turbulent and episodic symptom profiles on personal identity and recovery. Conclusions The novel challenges presented by Long COVID are complex with varying inter-related factors that are broadly impacting functional status and quality of life. Support mechanisms must incorporate the lived experiences and foster true collaborations between health professionals, patients and researchers to improve patient outcomes. Trial registration number NCT04649957.
Top Cited PapersOpen AccessLived experience of patients with Long COVID: a qualitative study in the UK
Background Long COVID is a rapidly evolving global health crisis requiring interdisciplinary support strategies that incorporate the lived experience of patients. Currently, there is a paucity of research documenting the day-to-day experiences of patients living with Long COVID. Objective To explore the lived experience of Long COVID patients. Study design Longitudinal, observation study. Setting An inductive, data-driven, qualitative approach was used to evaluate hand-written diaries obtained from individuals who had been referred to a Derbyshire Long COVID clinic. Participants 12 participants (11 females, age 49±10 years, 11 Caucasians) were recruited. Participants were included if they had a previous confirmed or suspected COVID-19 infection with ongoing recovery, >18 years old, understood the study requirements and provided informed consent. Method Participants were directed to complete self-report diaries over 16 weeks. Responses were transcribed verbatim and analysed using thematic analysis. Results Three key themes were highlighted: (1) understanding who helps patients manage symptoms, (2) daily activities and the impact on quality of life and health status and (3) the effect of turbulent and episodic symptom profiles on personal identity and recovery. Conclusions The novel challenges presented by Long COVID are complex with varying inter-related factors that are broadly impacting functional status and quality of life. Support mechanisms must incorporate the lived experiences and foster true collaborations between health professionals, patients and researchers to improve patient outcomes. Trial registration number NCT04649957.
- Open Access
- 26 October 2022
- Published by International Society of Global Health in Journal of Global Health
- Vol. 12, 03067
Is long COVID the next global health crisis?
The rapid development and deployment of coronavirus disease 2019 (COVID-19) vaccines should be heralded as a feat of true scientific collaboration that saved millions of lives [1]. Despite the success, vaccines do not offer complete protection against infection, mild, and severe disease [2–5] and the development of a long-term complex symptom profile, commonly referred to […]
- 26 October 2022
- Published by International Society of Global Health in Journal of Global Health
- Vol. 12, 03067
Open AccessIs long COVID the next global health crisis?
The rapid development and deployment of coronavirus disease 2019 (COVID-19) vaccines should be heralded as a feat of true scientific collaboration that saved millions of lives [1]. Despite the success, vaccines do not offer complete protection against infection, mild, and severe disease [2–5] and the development of a long-term complex symptom profile, commonly referred to […]
- Open Access
- 13 September 2022
- Published by Elsevier in Radiography
- Vol. 28, S93-S99
Post-acute COVID syndrome (long COVID): What should radiographers know and the potential impact for imaging services
- 13 September 2022
- Published by Elsevier in Radiography
- Vol. 28, S93-S99
Open AccessPost-acute COVID syndrome (long COVID): What should radiographers know and the potential impact for imaging services
- 1 September 2020
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 8  (9) , 852
Integrated sports and respiratory medicine in the aftermath of COVID-19
- 1 September 2020
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 8  (9) , 852
Integrated sports and respiratory medicine in the aftermath of COVID-19
- Open Access
- 10 April 2019
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 27  (12) , 4763-4770
Cross-sectional study of patient-reported fatigue, physical activity and cardiovascular status in men after robotic-assisted radical prostatectomy
Patient-reported fatigue after robotic-assisted radical prostatectomy (RARP) has not been characterised to date. Fatigue after other prostate cancer (PCa) treatments is known to impact on patient-reported quality of life. The aim of this study was to characterise fatigue, physical activity levels and cardiovascular status post-RARP.
- 10 April 2019
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 27  (12) , 4763-4770
Open AccessCross-sectional study of patient-reported fatigue, physical activity and cardiovascular status in men after robotic-assisted radical prostatectomy
Patient-reported fatigue after robotic-assisted radical prostatectomy (RARP) has not been characterised to date. Fatigue after other prostate cancer (PCa) treatments is known to impact on patient-reported quality of life. The aim of this study was to characterise fatigue, physical activity levels and cardiovascular status post-RARP.